CytRx to Present at the Biotech Showcase 2011 Conference

LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, MD, Ph.D., will present at the Biotech Showcase 2011 conference on Tuesday, January 11, 2011, at 10:45 a.m. Pacific time. The conference is being held at the Parc 55 Wyndham hotel in San Francisco.

“We look forward to sharing our strategy and plans for success at this conference that attracts investors interested specifically in our industry,” said Mr. Kriegsman. "We made considerable progress in advancing our oncology development programs last year as evidenced by our initiation of four oncology clinical trials. We expect an equally exciting 2011 as our plans include starting additional clinical trials and advancing ongoing studies."

Information about the Biotech Showcase 2011 conference is available at www.ebdgroup.com/bts.

About CytRx Corporation

Los Angeles-based CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: bafetinib, tamibarotene and INNO-206. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer, and is conducting a pharmacokinetic clinical trial in brain cancer. With its tumor-targeting pro-drug candidate INNO-206, CytRx plans to initiate Phase 2 proof-of-concept clinical trials as a treatment for pancreatic cancer and soft tissue sarcomas, following an abbreviated safety trial. CytRx's pipeline also includes tamibarotene, which it is testing in patients with non-small-cell lung cancer and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL). For more information on the Company, visit http://www.cytrx.com.



CONTACT:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.